<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856516</url>
  </required_header>
  <id_info>
    <org_study_id>15.11.US.HCN</org_study_id>
    <nct_id>NCT02856516</nct_id>
  </id_info>
  <brief_title>Glycemic Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Plasma Glucose and Insulin Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, cross-over design. Subjects will be randomized to one of three
      interventions on three separate study days, 1 week apart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following consent, subjects will be randomized to one of three arms. After an overnight fast
      an intravenous line will be placed for blood withdrawal. The subject will then consume the
      randomly assigned intervention. Blood samples for glucose and insulin levels will be drawn at
      specified intervals after the product has been consumed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the blood glucose curve (AUC 0-240)</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin curves (AUC 0-240)</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic index (Ins30/(Glu30)</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-30min) for insulin</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Boost Glucose Control (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boost Glucose Control (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boost Original</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Boost Glucose Control (A)</intervention_name>
    <description>Oral nutrition supplement</description>
    <arm_group_label>Boost Glucose Control (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Boost Glucose Control (B)</intervention_name>
    <description>Oral nutrition supplement</description>
    <arm_group_label>Boost Glucose Control (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Boost Original</intervention_name>
    <description>Oral nutrition supplement</description>
    <arm_group_label>Boost Original</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-75 yrs

          -  Type 2 diabetes controlled with diet or diet and oral agent, with the exception of
             sulfonylureas such as glimepiride (Amaryl), glipizide (Glucotrol/Glucotrol XL) and
             glyburide (DiaBeta, Micronase, (Glynase Prestabs); meglitinides such as reaglinide
             (Prandin) and nateglinide (Starlix); and alphaglucosidase inhibitors such as acarbose
             (Precose) and miglitol (Glyset)

          -  Hemoglobin A1C less than 9.0%

          -  Fasting blood glucose less than 180 mg

        Exclusion Criteria:

          -  Abnormal thyroid function

          -  Creatinine &gt;2.0 mg/dL

          -  Potassium &lt;3.5 mEq/L

          -  Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting

          -  Currently unstable diabetes or under treatment for cancer, heart disease, renal
             disease

          -  Unable to give informed consent or follow instructions

          -  Current insulin therapy or insulin therapy within the past month

          -  Patients who are pregnant

          -  Allergies to milk, soy or any component of the test product

          -  Patient who in the Investigators assessment cannot be expected to comply with
             treatment

          -  Currently participating or having participated in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Neutel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be presented in a peer reviewed manuscript</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

